Editorial: Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: A new alternative?

Neurocritical Care

Volumn 11, Issue 1, 2009, Pages 1-4

  Fields, Jeremy D ^a   Bhardwaj, Anish ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ARGIPRESSIN; CONIVAPTAN; FLUDROCORTISONE; LIXIVAPTAN; MOZAVAPTAN; PEPTIDE HORMONE ANTAGONIST; RELCOVAPTAN; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; BENZAZEPINE DERIVATIVE;

BODY WATER; CONTINUOUS INFUSION; DISEASE SEVERITY; HUMAN; HYPONATREMIA; HYPOTHALAMUS; INJECTION SITE REACTION; INTENSIVE CARE; NEUROHYPOPHYSIS; NEUROLOGIC DISEASE; OSMOLALITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WATER PERMEABILITY; DRUG ANTAGONISM; EDITORIAL; METABOLISM; METHODOLOGY;

ARGININE VASOPRESSIN; BENZAZEPINES; CRITICAL CARE; HUMANS; HYPONATREMIA;

EID: 65449167174     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-009-9224-x     Document Type: Review

References (18)

1. Y Chang TY Chen CH Chen, et al. 2006 Plasma arginine-vasopressin following experimental stroke: efffect of osmotherapy J Appl Physiol 100 1445 1451 10.1152/japplphysiol.00763.2005 16339345 10.1152/japplphysiol.00763.2005 1:CAS:528:DC%2BD28XltVWltrc%3D
2. H Niermann M Amiry-Moghaddam K Holtoff, et al. 2001 A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex J Neurosci 21 3045 3051 11312289 1:CAS:528:DC%2BD3MXjtFyqur4%3D
3. G Decaux A Soupart G Vassart 2008 Non-peptide arginine-vasopressin antagonists: the vaptans Lancet 371 1624 1632 10.1016/S0140-6736(08)60695-9 18468546 10.1016/S0140-6736(08)60695-9 1:CAS:528:DC%2BD1cXlslWhsbc%3D (Pubitemid 351626846)
4. O Bloch GT Manley 2007 The role of aquaporin-4 in cerebral water transport and edema Neurosurg Focus 22 E3 10.3171/foc.2007.22.5.4 17613234 10.3171/foc.2007.22.5.4
5. CL Holmes DW Landry JT Granton 2003 Science review: vasopressin and the cardiovascular system part 1-receptor physiology Crit Care 7 427 434 10.1186/cc2337 14624682 10.1186/cc2337 (Pubitemid 37527228)
6. A Bhardwaj 2006 Neurological impact of vasopressin dysregulation and hyponatremia Ann Neurol 59 229 236 10.1002/ana.20788 16437573 10.1002/ana.20788 1:CAS:528:DC%2BD28XhvVSlu7s%3D (Pubitemid 43202475)
7. DH Ellison T Berl 2007 Clinical practice. The syndrome of inappropriate antidiuresis N Engl J Med 356 2064 2072 10.1056/NEJMcp066837 17507705 10.1056/NEJMcp066837 1:CAS:528:DC%2BD2sXlsFGgtb8%3D (Pubitemid 46789896)
8. F Ali M Guglin P Vaitkevicius JK Ghali 2007 Therapeutic potential of vasopressin receptor antagonists Drugs 67 847 858 10.2165/00003495-200767060- 00002 17428103 10.2165/00003495-200767060-00002 1:CAS:528:DC%2BD2sXmt1emtrk%3D
9. AA Rabinstein EF Wijdicks 2003 Hyponatremia in critically ill neurological patients Neurologist 9 290 300 10.1097/01.nrl.0000095258.07720.89 14629783 10.1097/01.nrl.0000095258.07720.89 (Pubitemid 37484848)
10. BR Nathan 2007 Cerebral correlates of hyponatremia Neurocrit Care 6 72 78 10.1385/NCC:6:1:72 17356196 10.1385/NCC:6:1:72 1:CAS:528:DC%2BD2sXnsVSktrg%3D (Pubitemid 46424456)
11. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009 Jan 4. [Epub ahead of print].
12. Wright WL, Asbury WH, Gilmore JL, Samuels OB. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care. 2008 Nov 12. [Epub ahead of print].
13. JE Udelson C Orlandi J Ouyang, et al. 2008 Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol 52 19 1540 1545 10.1016/j.jacc.2008. 08.013 19007589 10.1016/j.jacc.2008.08.013 1:CAS:528:DC%2BD1cXhtlahtbjK
14. E Zeynalov CH Chen SC Froehner, et al. 2008 The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema Crit Care Med 36 2634 2640 10.1097/CCM.0b013e3181847853 18679106 10.1097/CCM.0b013e3181847853 1:CAS:528:DC%2BD1cXhtVejs7fJ
15. R Trabold S Krieg K Scholler N Plesnila 2008 Role of vasopressin v(1a) and v(2) receptors for the development of secondary brain damage after traumatic brain injury in mice J Neurotrauma 25 12 1459 1465 19118456 10.1089/neu.2008.0597
16. A Kleindienst G Fazzina JG Dunbar R Glisson A Marmarou 2006 Protective effect of the v1a receptor antagonist sr49059 on brain edema formation following middle cerebral artery occlusion in the rat Acta Neurochir Suppl (Wien) 96 303 306 10.1007/3-211-30714-1-65 10.1007/3-211-30714-1-65 1:STN:280: DC%2BD283kslKqsg%3D%3D
17. AH Molnár C Varga A Berkó, et al. 2008 Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260 Prog Brain Res 170 519 525 10.1016/S0079-6123(08)00439-1 18655905 10.1016/S0079-6123(08)00439-1 (Pubitemid 352024379)
18. Y Ikeda A Teramoto Y Nakagawa, et al. 1997 Attenuation of cryogenic induced brain oedema by arginine vasopressin release inhibitor RU51599 Acta Neurochir (Wien) 139 12 1173 1179 10.1007/BF01410979 10.1007/BF01410979 1:STN:280:DyaK1c7ktVSgug%3D%3D (Pubitemid 28014899)